Nymox Pharmaceutical (NYMX) Short Interest Ratio & Short Volume → The Crypto 9-5 Escape Plan (From Crypto 101 Media) (Ad) Free NYMX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Short InterestStock Analysis Nymox Pharmaceutical Short Interest DataCurrent Short Volume2,030,000 sharesPrevious Short Volume2,070,000 sharesChange Vs. Previous Month-1.93%Dollar Volume Sold Short$782,971.00Short Interest Ratio / Days to Cover42.6Last Record DateJune 15, 2023Outstanding Shares90,510,000 sharesFloat Size46,310,000 sharesShort Percent of Float4.38%Today's Trading Volume932,700 sharesAverage Trading Volume94,622 sharesToday's Volume Vs. Average986% Short Selling Nymox Pharmaceutical ? Sign up to receive the latest short interest report for Nymox Pharmaceutical and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatNYMX Short Interest Over TimeNYMX Days to Cover Over TimeNYMX Percentage of Float Shorted Over Time Ad Behind the MarketsThe Weight Loss Pill That Could Disrupt a $32 Billion IndustryA revolutionary new weight loss pill is about to send shockwaves through the plus-size clothing market. Analysts are calling it the "King Kong" of diet drugs after amazing clinical trial results.Don't miss out on the "next Ozempic" >>> Nymox Pharmaceutical Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 6/15/20232,030,000 shares $782,971.00 -1.9%4.4%42.6 $0.39 5/31/20232,070,000 shares $869,607.00 -0.5%4.6%42.9 $0.42 5/15/20232,080,000 shares $773,760.00 -3.3%4.6%38.4 $0.37 4/30/20232,150,000 shares $838,715.00 -1.8%4.8%38.5 $0.39 4/15/20232,190,000 shares $917,610.00 +7.4%4.8%37 $0.42 3/31/20232,040,000 shares $693,600.00 -5.6%4.5%37.7 $0.34 Get the Latest News and Ratings for NYMX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Nymox Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. 3/15/20232,160,000 shares $820,584.00 -0.9%4.8%31.5 $0.38 2/28/20232,180,000 shares $763,000.00 -0.5%4.1%11.5 $0.35 2/15/20232,190,000 shares $974,112.00 +15.3%4.2%11.4 $0.44 1/31/20231,900,000 shares $813,010.00 +2.2%3.6%9.9 $0.43 1/15/20231,860,000 shares $809,098.14 -4.6%3.5%9.7 $0.43 12/30/20221,950,000 shares $630,435.00 +6.0%3.6%10 $0.32 12/15/20221,840,000 shares $731,768.00 +5.1%3.4%9.8 $0.40 11/30/20221,750,000 shares $533,750.00 No Change3.3%9.9 $0.31 11/15/20221,750,000 shares $544,250.00 -3.9%3.3%23.6 $0.31 10/31/20221,820,000 shares $673,400.00 +6.4%3.4%18.5 $0.37 10/15/20221,710,000 shares $563,274.00 -2.8%3.2%15.4 $0.33 9/30/20221,760,000 shares $729,872.00 -3.3%3.3%5.6 $0.41 9/15/20221,820,000 shares $728,000.00 +4.0%3.4%5.6 $0.40 8/31/20221,750,000 shares $770,000.00 -4.4%3.3%5 $0.44 8/15/20221,830,000 shares $923,967.00 -12.4%3.5%3.9 $0.50 7/31/20222,090,000 shares $781,869.00 +7.2%4.0%4.6 $0.37 7/15/20221,950,000 shares $585,000.00 -2.0%3.7%4.4 $0.30 6/30/20221,990,000 shares $865,650.00 -2.5%3.8%8.1 $0.44 6/15/20222,040,000 shares $920,244.00 +12.1%3.9%8.2 $0.45 5/31/20221,820,000 shares $728,000.00 +7.1%3.5%5.9 $0.40 5/15/20221,700,000 shares $2.19 million -1.2%3.2%5.6 $1.29 4/30/20221,720,000 shares $2.03 million -8.5%3.3%8.2 $1.18 4/15/20221,880,000 shares $2.63 million -11.7%3.6%8.8 $1.40 3/31/20222,130,000 shares $2.68 million -11.3%4.2%10.2 $1.26 3/15/20222,400,000 shares $4.49 million +8.1%5.0%7.5 $1.87 2/28/20222,220,000 shares $3.89 million -2.2%4.6%9 $1.75 2/15/20222,270,000 shares $3.36 million +1.8%4.7%10.3 $1.48 1/31/20222,230,000 shares $3.48 million -14.6%4.6%10.5 $1.56 1/15/20222,610,000 shares $4.18 million +26.1%5.4%12.5 $1.60 12/31/20212,070,000 shares $2.69 million -11.2%4.3%10 $1.30 12/15/20212,330,000 shares $2.49 million +8.4%4.8%31.3 $1.07 11/30/20212,150,000 shares $3.05 million -1.4%4.7%27.5 $1.42 11/15/20212,180,000 shares $3.55 million -9.2%5.0%23.8 $1.63 10/29/20212,400,000 shares $4.27 million -3.6%5.5%14.1 $1.78Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now NYMX Short Interest - Frequently Asked Questions What is Nymox Pharmaceutical's current short interest? Short interest is the volume of Nymox Pharmaceutical shares that have been sold short but have not yet been closed out or covered. As of June 15th, traders have sold 2,030,000 shares of NYMX short. 4.38% of Nymox Pharmaceutical's shares are currently sold short. Learn More on Nymox Pharmaceutical's current short interest. What is a good short interest ratio for Nymox Pharmaceutical? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. NYMX shares currently have a short interest ratio of 43.0. Learn More on Nymox Pharmaceutical's short interest ratio. What is a good short interest percentage for Nymox Pharmaceutical? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 4.38% of Nymox Pharmaceutical's floating shares are currently sold short. Is Nymox Pharmaceutical's short interest increasing or decreasing? Nymox Pharmaceutical saw a drop in short interest during the month of June. As of June 15th, there was short interest totaling 2,030,000 shares, a drop of 1.9% from the previous total of 2,070,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Nymox Pharmaceutical's float size? Nymox Pharmaceutical currently has issued a total of 90,510,000 shares. Some of Nymox Pharmaceutical's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Nymox Pharmaceutical currently has a public float of 46,310,000 shares. How does Nymox Pharmaceutical's short interest compare to its competitors? 4.38% of Nymox Pharmaceutical's shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Nymox Pharmaceutical: Cardio Diagnostics Holdings, Inc. (2.91%), OncoCyte Co. (3.08%), Trinity Biotech plc (0.03%), Biomerica, Inc. (0.39%), MyMD Pharmaceuticals, Inc. (20.58%), Aspira Women's Health Inc. (2.52%), ImmuCell Co. (0.08%), ARCA biopharma, Inc. (39.55%), Orgenesis Inc. (1.17%), T2 Biosystems, Inc. (6.79%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.80 billion), Canadian Natural Resources Limited ($3.69 billion), Charter Communications, Inc. ($2.95 billion), Occidental Petroleum Co. ($2.78 billion), Moderna, Inc. ($2.38 billion), Palantir Technologies Inc. ($2.29 billion), T. Rowe Price Group, Inc. ($2.19 billion), Coinbase Global, Inc. ($2.08 billion), Royal Caribbean Cruises Ltd. ($2.02 billion), and Verisk Analytics, Inc. ($1.96 billion). View all of the most shorted stocks. What does it mean to sell short Nymox Pharmaceutical stock? Short selling NYMX is an investing strategy that aims to generate trading profit from Nymox Pharmaceutical as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Nymox Pharmaceutical? A short squeeze for Nymox Pharmaceutical occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of NYMX, which in turn drives the price of the stock up even further. How often is Nymox Pharmaceutical's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including NYMX, twice per month. The most recent reporting period available is June, 15 2023. More Short Interest Resources from MarketBeat Related Companies: Cardio Diagnostics Short Interest OncoCyte Short Interest Trinity Biotech Short Interest Biomerica Short Interest MyMD Pharmaceuticals Short Interest Aspira Women's Health Short Interest ImmuCell Short Interest ARCA biopharma Short Interest Orgenesis Short Interest T2 Biosystems Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:NYMX) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersThe Crypto 9-5 Escape PlanCrypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeHe Is Giving Away BitcoinCrypto Swap ProfitsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward PressThe 2024 Gold Rush: Unleashing Market PotentialPriority Gold[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings